Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Tiziana Life Sciences ( (TLSA) ).
On October 29, 2025, Tiziana Life Sciences announced its participation as a presenting company at BIO-Europe 2025, a leading life sciences partnering conference in Vienna. The company plans to highlight its innovative nasal delivery platform and lead candidate, intranasal foralumab, which is in clinical development for conditions like non-active secondary progressive multiple sclerosis and early Alzheimer’s disease. Tiziana’s involvement in the conference underscores its commitment to advancing novel therapies that modulate immune responses through alternative delivery routes, potentially transforming treatment paradigms for chronic neurological conditions.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies. The company’s primary product is intranasal foralumab, a fully human anti-CD3 monoclonal antibody, which aims to improve efficacy, safety, and tolerability over traditional intravenous methods. Tiziana targets neuroinflammatory and neurodegenerative diseases, such as multiple sclerosis and Alzheimer’s, with its proprietary nasal delivery platform.
Average Trading Volume: 427,342
Technical Sentiment Signal: Buy
Current Market Cap: $217.4M
See more data about TLSA stock on TipRanks’ Stock Analysis page.